denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Session: 906. Outcomes Research—Myeloid Malignancies: Poster II
Hematology Disease Topics & Pathways:
Research, Diseases, Myeloid Malignancies
Methods: Patients enrolled in MOST were aged ≥18 years with clinical diagnoses of MF or ET at clinical practices within the United States. Patients with MF included those with primary or secondary MF who were low risk (or intermediate-1 by age >65 years alone) per the Dynamic International Prognostic Scoring System (Passamonti F, et al. Blood. 2010;115:1703-1708). Patients in the ET cohort had a clinical diagnosis of ET and were ≥60 years or had history of thromboembolic events or were receiving ET-directed therapy at enrollment. Descriptive statistics were used to summarize the data. The median (range) follow-up time for CALR- and JAK2-positive patients was 52.8 (43-68) months and 56.6 (42-70) months, respectively. ET progression was defined as transformation to MF; MF progression was defined as worsening of objective clinical and laboratory assessments of disease.
Results: A total of 881 patients (CALR-positive, n=137 [16%]; JAK2-positive, n=750 [85%]; 6 patients had both CALR and JAK2 mutations) were included in this study. A summary of patient and disease characteristics are presented in Table 1 and Table 2. At enrollment, 25% and 75% of CALR-positive patients had a diagnosis of MF and ET, respectively, vs 16% and 84% of JAK2-positive patients. The majority of patients in both groups were women (CALR-positive, 56%; JAK2-positive, 65%). CALR-positive patients were younger at enrollment and at diagnosis compared with JAK2-positive patients (median age at enrollment, 63.0 [24.0-89.0] vs 70.0 [26.0-93.0] years, P<0.001; median age at diagnosis, 59.3 [21.0-87.0] vs 66.3 [22.0-93.0] years, P<0.001).
The majority of patients in this analysis (79% of CALR-positive, 90% of JAK2-positive) were receiving MPN-directed therapy at enrollment. The most common therapies in the CALR cohort were hydroxyurea (51%), interferon (12%), and anagrelide (8%); the common therapies among patients in the JAK2 cohort were hydroxyurea (66%), aspirin only (10%), and ruxolitinib (8%). Disease burden at enrollment was also assessed. The percentages of patients with white blood cell (WBC) count >10×109/L or platelet count >400×109/L were similar for both CALR- and JAK2-positive patients (13% vs 20% and 53% vs 51%, respectively). Percentages of patients with splenomegaly (SPM) were similar for CALR- vs JAK2-positive patients at enrollment (11.0% vs 13%). The mean MPN-SAF TSS was similar at baseline for CALR- and JAK2-positive patients (15.1 vs 16.5). The percentage of patients with MPN-SAF TSS >25 was 12% in the CALR-positive and 16% in JAK2-positive cohorts.
Disease complications and progression were also assessed. Thrombotic and hemorrhagic events during the study period were infrequent in both CALR- and JAK2-positive patients (2% vs 4% and 1% vs 3%, respectively). Rates of disease progression were similar for CALR- and JAK2-positive patients, both for MF progression (50% vs 61%) and for ET progression to MF (2% vs 5%). Leukemic transformation occurred in 6 (4%) CALR-positive patients and 43 (6%) JAK2-positive patients. Deaths due to disease progression occurred in no CALR-positive patients and in 18 (2%) JAK2-positive patients.
Conclusions: The results of this real-world analysis of the MOST study demonstrate that despite nearly 80% of CALR-positive patients receiving MPN-directed treatment, a substantial percentage of this group did not meet treatment goals, including control of symptom burden, WBC and platelet counts, and SPM. In addition, disease progression was observed in 50% of the patients with MF in the CALR-positive cohort. Further analysis of the MOST study may provide insight into optimal management of patients with CALR mutations.
Disclosures: Oh: CTI BioPharma, Bristol Myers Squibb, Disc Medicine, Blueprint Medicines, PharmaEssentia, Constellation/MorphoSys, Geron, AbbVie, Sierra Oncology/GSK, Cogent, Incyte, Morphic, Protagonist: Consultancy. Pemmaraju: Menarini Group: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ASH Committee on Communications: Other: Leadership; ASCO Cancer.Net Editorial Board: Other: Leadership; National Institute of Health/National Cancer Institute (NIH/NCI): Research Funding; Magdalen Medical Publishing: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; EUSA Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Stemline: Consultancy, Membership on an entity's Board of Directors or advisory committees; Intellisphere: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Aplastic Anemia & MDS International Foundation: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Dava Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CTI BioPharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Dan's House of Hope: Membership on an entity's Board of Directors or advisory committees; Harborside Press: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Curio Science: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CancerNet: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Medscape: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; PeerView Institute for Medical Education: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Physician Education Resource (PER): Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; OncLive: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Imedex: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ImmunoGen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Karger Publishers: Other: Licenses; United States Department of Defense (DOD): Research Funding; Protagonist Therapeutics, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees; CareDx: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pacylex: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; HemOnc Times/Oncology Times: Other: Uncompensated; ClearView Healthcare Partners: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; PharmaEssentia: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees; Neopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Patient Power: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Cimeio Therapeutics AG: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Blueprint: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Aptitude Health: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Bristol Myers Squibb Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Braunstein: Incyte Corporation: Current Employment, Current equity holder in private company, Current holder of stock options in a privately-held company. Hamer-Maansson: Incyte Corporation: Current Employment, Current equity holder in private company, Current holder of stock options in a privately-held company. Kalafut: Incyte Corporation: Current Employment, Current equity holder in publicly-traded company. Ritchie: Novartis: Consultancy, Other: Travel Support, Research Funding, Speakers Bureau; Ariad: Speakers Bureau; Bristol Myers Squibb: Consultancy, Research Funding; Astellas Pharma, Jazz Pharmaceuticals, NS Pharma: Research Funding; Pfizer: Consultancy, Other: travel, Research Funding; Celgene, Incyte Corporation, Novartis: Consultancy; Celgene: Other: Travel Support, Speakers Bureau.
See more of: Oral and Poster Abstracts